Remdesivir In COVID-19 Patients Research Articles

Efficacy and safety of favipiravir and remdesivir in COVID-19 patients: Clinical data

Aim. To evaluate the efficacy and safety of favipiravir and remdesivir in the infectious disease hospital of the Volgograd region in 2022. Materials and methods. In total, 559 medical records of patients prescribed favipiravir or remdesivir in 2022 were studied. Long-term results of the drug use and disease outcomes after discharge or transfer to another medical institution were assessed using the Federal registry of people with COVID-19. Results. Favipiravir was more frequently prescribed in mild cases of the disease. After excluding patients without signs of lung injury from the analysis, there were no significant differences in mortality and improvement. Patients receiving favipiravir had lower odds of ALT elevations above 5 upper limits of normal and developing drug-induced liver injury with a possible RUCAM score compared with patients receiving remdesivir (OR = 0.40, 95CI 0.20–0.80 and OR = 0.30, 95 CI 0.08–1.08). Conclusion. The limited experience of the use of favipiravir for COVID-19 necessitates further research into its efficacy and safety, particularly when prescribing warfarin and high doses of direct anticoagulants simultaneously.

Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center

Background: One of the FDA-approved treatments for COVID-19 is remdesivir. In this study, we investigated adverse drug events (ADEs) of remdesivir in COVID-19 patients who contacted 13-Aban pharmacy’s drug and poison information center (DPIC). Methods: In this study, data of patients receiving remdesivir who contacted the 13-Aban pharmacy’s DPIC between April 2021 and May 2022 were extracted. For the evaluation of potential ADEs, we reviewed all contacts related to remdesivir recipients. Results: Out of 223 patients enrolled, 108 (48.40%) developed 120 ADEs. Elevated liver transaminase levels (26.67%) were the most common ADE, followed by weakness (7.5%), nausea, and vomiting (7.5%). The causality assessment of ADE using the Naranjo scale revealed that 41.67% were probable and 58.33% were possible. Conclusion: Based on the results of this study, hepatic dysfunction was the most prevalent ADE among remdesivir recipients; thus, in order to ensure safe use of remdesivir, patients should be closely monitored for this ADE.

Remdesivir in COVID-19 Patients with Kidney Disease: A Study on the Renal Function and Outcomes

Remdesivir in COVID-19 Patients with Kidney Disease: A Study on the Renal Function and Outcomes

Exploring Adverse Events of Remdesivir in Covid-19 Patients: A Comprehensive Global Analysis

Background: The emergence of COVID-19, stemming from SARS-CoV-2, has triggered a global pandemic, urging rapid therapeutic interventions. Remdesivir, a nucleotide analog prodrug, garnered attention for its potential against COVID-19 due to in vitro efficacy against coronaviruses. This study reviews Remdesivir’s adverse effects in COVID-19 patients. Methodology: While Remdesivir shows promise, recent studies raise efficacy concerns. Adverse drug event (ADE) documentation is vital due to limited pre-pandemic ADE data. WHO VigiBase® analysis (2015-2020) and COVID-19 ADE studies were undertaken, focusing on age, severity, region, and organ impact. 1086 ADEs emerged from 439 case reports by July 19, 2020, in VigiBase®, reducing to 1004 after duplicates were removed. ADEs primarily related to COVID-19 patients (92.5%), notably from the Americas (67.7%). Mainly in males above 45, ADEs were serious (82.5%). Key ADEs encompassed elevated hepatic enzymes (32.1%), renal damage (14.4%), increased creatinine levels (11.2%), and respiratory failure (6.4%). Conclusion: Liver and kidney function deterioration emerged as frequent ADEs, underscoring the need for vigilance during Remdesivir treatment. These findings align with regulatory documents. In sum, COVID-19 has prompted swift therapeutic responses, with Remdesivir being explored as a potential treatment. This study sheds light on associated ADEs, highlighting the importance of monitoring and informed decision-making

Publication bias in meta-analyses of the therapeutic efficacy of remdesivir interventions for patients with COVID-19

Purpose No comprehensive statistical assessment of publication bias has been conducted in remdesivir-based intervention research for COVID-19 patients. This study aims to examine all meta-analyses of the efficacy of remdesivir interventions in COVID-19 patients and perform a statistical assessment of publication bias. Design/methodology/approach This is an analytic study conducted to assess the impact of publication bias on the results of meta-analyses of remdesivir-based interventions in patients infected with COVID-19. All English full-text meta-analyses published in peer-reviewed journals in 2019–2021 were included. A computerized search of PubMed and Web of Science electronic databases was performed on December 24, 2021. The trim-and-fill method calculated the number of missing studies and the adjusted cumulative effect sizes. Findings The final analysis comprised 21 studies with 88 outcomes. The investigation revealed missing studies in 46 outcomes (52%). Seventy-six missing studies were replaced in the outcomes using the trim-and-fill procedure. The adjusted recalculated effect sizes of the 27 outcomes increased by an average of 0.04. In comparison, the adjusted effect size of 18 outcomes fell by an average of 0.036. Only 14 out of 46 outcomes with publication bias were subjected to a gray literature search (30%). To discover related research, no gray literature search was conducted in most outcomes with publication bias (n = 32; 70%). In conclusion, the reported effect estimates regarding the effect of remdesivir in COVID-19 patients are only slightly affected by publication bias and can be considered authentic. Health-care decision-makers in COVID-19 should consider current research results when making clinical decisions. Research limitations/implications Most health decisions are based on the effect sizes revealed in meta-analyses. When deciding on remdesivir-based treatment for COVID-19 patients, therefore, the outcomes of this investigation may be of paramount importance to health policymakers, leading to better treatment strategies. Practical implications According to the results, no major publication bias and missing studies were detected on average. Therefore, the calculated effect sizes of remdesivir-based interventions on meta-analyses can be used as authentic and unbiased benchmarks by health-care decision-makers in treating patients with COVID-19. Originality/value This is the first study to examine the effect of publication bias and gray literature searches on the results of meta-analyses of treatment with COVID-19 (remdesivir).

Exploring Adverse Events of Remdesivir in Covid-19 Patients: A Comprehensive Global Analysis

Background: The emergence of COVID-19, stemming from SARS-CoV-2, has triggered a global pandemic, urging rapid therapeutic interventions. Remdesivir, a nucleotide analog prodrug, garnered attention for its potential against COVID-19 due to in vitro efficacy against coronaviruses. This study reviews Remdesivir’s adverse effects in COVID-19 patients. Methodology: While Remdesivir shows promise, recent studies raise efficacy concerns. Adverse drug event (ADE) documentation is vital due to limited pre-pandemic ADE data. WHO VigiBase® analysis (2015-2020) and COVID-19 ADE studies were undertaken, focusing on age, severity, region, and organ impact. 1086 ADEs emerged from 439 case reports by July 19, 2020, in VigiBase®, reducing to 1004 after duplicates were removed. ADEs primarily related to COVID-19 patients (92.5%), notably from the Americas (67.7%). Mainly in males above 45, ADEs were serious (82.5%). Key ADEs encompassed elevated hepatic enzymes (32.1%), renal damage (14.4%), increased creatinine levels (11.2%), and respiratory failure (6.4%). Conclusion: Liver and kidney function deterioration emerged as frequent ADEs, underscoring the need for vigilance during Remdesivir treatment. These findings align with regulatory documents. In sum, COVID-19 has prompted swift therapeutic responses, with Remdesivir being explored as a potential treatment. This study sheds light on associated ADEs, highlighting the importance of monitoring and informed decision-making

AN EVALUATION OF ADVERSE DRUG REACTIONS WITH REMDESIVIR IN PATIENTS OF COVID-19

Objectives: The aim of the study was to evaluate the adverse drug reactions (ADR) following Remdesivir therapy in patients of COVID-19. Methods: All patients more than 18 years of age of any gender, diagnosed with COVID-19 infection receiving remdesivir therapy and fulfilling the selection criteria were included in the study after informed consent. They were monitored for ADRs till end of treatment and analyzed for characteristics of the ADRs: Causality, severity, and preventability. Results: Out of 80 patients (mean age of 49.27±16.22 years) enrolled, 51 (63.75%) developed 84 ADRs. Most common ADRs included increased aspartate transaminases, (20.23%), increased bilirubin (19.04%), increased alanine transaminases (13.09%), increased creatinine (11.90%), and increased blood urea (9.52%). Causality assessment using WHO-UMC scale showed, 85.71% possible, 13.09% probable, and 1% certain causal association of the ADRs with remdesivir. A total 75% ADRs were mild in severity and 45% patients recovered from the event at the end of treatment. Conclusion: Hepatic and Renal dysfunctions are observed with remdesivir in COVID-19 patients. Intensive monitoring of ADRs with newer drugs with EUA such as remdesivir is warranted to ensure safer use in patients.

A Meta-Analysis of Safety of Different Regimens of Remdesivir in COVID-19 Patients

Remdesivir is an adenosine analogue drug that targets RNA-dependent RNA polymerase enzyme and inhibits viral replication. As of 22nd October, 2020, US FDA fully approved the drug Remdesivir for the treatment of COVID-19 patients who requires hospitalisation. Many clinical studies reported the derangement in hepatic and renal function tests, which is alarming considering the health conditions of the COVID-19 patients. In view of these results, the present study was envisaged to review the safety of Remdesivir in COVID-19 patients. The PubMed, Embase, and Cochrane databases were searched using the terms 'Remdesivir,' 'veklury,' 'SARS' and 'COVID' till 1st December, 2020. The studies included in this meta-analysis were either randomised or nonrandomised studies that evaluated Remdesivir for the treatment of COVID-19 against Placebo [standard of care]. The Adverse events [AEs], Serious adverse events [SAEs] and Treatment Discontinuation due to Adverse Events (TDAE) were used as primary outcome measures. The quality of studies was evaluated by using the Cochrane Collaboration's tool for the assessment of RoB. Data analysis was performed by two authors (MK & DB) using statistical software Review manager [Revman] version 5.3. The pooled Risk Ratios (RR) and 95% Confidence Intervals (CI) were calculated by using a random-effects model for both primary and secondary outcomes. A total of four RCTs were included for the meta-analysis. Out of the four included clinical trials accepted for its methodological quality, three were of excellent quality and one study was of moderate quality. The pooled estimates of the three studies showed that Remdesivir had a 24% lower risk of SAEs compared to the placebo arm. However, the pooled estimates of two studies showed that 10 days of Remdesivir had 56% higher risk of SAEs compared to 5 days of Remdesivir regimen. Similarly, the 10 days of Remdesivir had two times higher risk of TDAEs compared to 5 days Remdesivir regimen. In conclusion, our meta-analysis demonstrated that Remdesivir is a safe therapeutic option. Our metanalysis revealed 5 days' regimen have better safety profile than 10 days' regimen of drug Remdesivir with respect to SAEs and TDAEs. For hospitalized patients, a 5-day course could be preferable with fewer safety concerns and lower drug costs. PROSPERO Registration ID: CRD 42020224272.

Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports

BackgroundThe mortality rate of novel coronaviral disease (COVID-19) patients undergoing dialysis is considerably higher than that of patients with normal kidney function. As of August 2021, only remdesivir has been approved in Japan as an antiviral drug for the treatment of COVID-19. However, in cases of kidney failure, remdesivir administration should be considered only if the therapeutic benefits outweigh the risks because of concern about the accumulation of its solubilizing excipient sulfobutylether-beta-cyclodextrin and subsequent renal tubular injury or liver injury. Recently, reports from overseas indicating the safety of the use of remdesivir for COVID-19 patients on dialysis have been gathered.Case presentationFrom June 2021, in our hospital, we started the administration of remdesivir to patients with moderate cases of COVID-19 undergoing hemodialysis, with careful consideration of the dosage and timing. Since then, six out of seven COVID-19 patients on hemodialysis who had received remdesivir have completely recovered. In a patient who died, the initial dose of remdesivir was administered after the case developed into severe COVID-19. All six patients who were able to start receiving remdesivir immediately at the stage of moderate COVID-19 recovered and were discharged without the need for mechanical ventilation. While, two out of four patients before May 2021 who had not been administered remdesivir at admission became severe, transferred to another tertiary hospital, and died. During and after remdesivir administration, no increase in serum transaminase to five times or more of the normal upper limit was observed in any of the cases. There were no other adverse drug reactions, such as infusion reaction, gastrointestinal symptoms, or anemia.ConclusionsWe were able to administer remdesivir to six Japanese patients with moderate COVID-19 on hemodialysis safely. It is expected that the safe use of remdesivir will bring an increase in treatment options for moderate cases of COVID-19 in dialysis patients as well as subsequent improvement in treatment outcomes. However, to confirm the efficacy and safety of such use, further careful observation in more cases is required.

Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.

The aim of this report is to review the literature and shed light on the uncertainties surrounding the use of antiviral agents in general and remdesivir in COVID-19 patients. This review evaluated a battery of antiviral compounds and their effectiveness in the treatment of COVID-19 since the beginning of the pandemic. Remdesivir is the only antiviral approved by the EMA and FDA for the treatment of SARS-CoV-2 infection. This work extensively reviews remdesivir data generated from clinical trials and observational studies, paying attention to the most recent data, and focusing on outcomes to give readers a more comprehensive understanding of the results. This review also discusses the recommendations issued by official bodies during the pandemic in the light of the current knowledge. The use of remdesivir in the treatment of SARS-CoV-2 infection is justified because a virus is the causative agent that triggers the inflammatory responses and its consequences. More trials are needed to improve the management of this disease.

Role of Remdesivir in Covid-19 Patients: A Study from the Capital City of Pakistan

Background Coronavirus disease 2019, caused by SARS-COVID-19 has emerged as a pandemic. It usually causes severe respiratory disease. Characteristically it undergoes genetic variability and newer strains emerge as a result of genetic mutations or environmental factors. It makes it difficult to be treated. We used remdesivir in our hospital to treat covid-19 patients. The aim of our study was to evaluate the role of remdesivir in COVID-19 patients. Patients and Methods We conducted a descriptive cross sectional study on the patients admitted in the department of Medicine, Capital hospital, Islamabad, Pakistan from November 2020 to October 2021. All patients aged 14 years and above were included. Both SARS-CoV-2 positive patients by molecular biology and COVID suspected cases, selected on the basis of low oxygen saturation, deranged inflammatory markers, positive contact history and radiological findings with negative COVID19 PCR testing were included in the study. The data was compiled using Microsoft Excel and later was analyzed on SPSS version 24. Results Among 669 patients, 375 (56.1 %) were males and 294 (43.9%) were females. Median age of patients was 58.2 years. 349 (52.2%) were COVID PCR positive and 320 (47.8%) were PCR negative. Out of 669 patients 573 (85.7%) were discharged and 96 (14.3%) expired. Inflammatory markers before and after the treatment were measured with overall significant decrease (P-value 0.000) after treatment. Patients were divided into two groups, remdesivir given (n=436) and remdesivir not given (n=233). Hospital stay was of shorter duration among 249(57.6%) in remdesivir given group than in remdesivir not given group 183(42.4%). While evaluating outcome 370(64.6%) patients were discharged and 66(68.7%) expired in remdesivir given group and 203 (35.4%) patients were discharged and 30 (31.3%) expired in second group. Lactic dehydrogenase (LDH) level was raised (>480 U/L) in 378(68.5%) patients before taking remdesivir and was raised only in 209(47.9%) patients after taking remdesivir (P-0.027). Conclusion Our study revealed that Hospital stay was shorter (P-value 0.000) in remdesivir given group. There was no significant effect of remdesivir on patient’s outcome and mortality (P-value 0.250). Only Lactic dehydrogenase was significantly decreased (p-value 0.027) in remdesivir given group. Key words COVID-19, Remdesivir, outcome, Inflammatory markers

EFFICACY AND SAFETY OF REMDESIVIR IN INDIAN PATIENTS WITH MODERATE TO SEVERE COVID-19: RESULTS FROM THE OPEN LABEL PERIOD OF A PHASE II, RANDOMIZED CONTROLLED TRIAL

BACKGROUND: Remdesivir has proved its antiviral efcacy on COVID-19 virus in-vitro, but its role in infected patients is still obscure. OBJECTIVE:To evaluate the efcacy and safety of Remdesivir in COVID-19 patients with signicant pulmonary involvement. STUDYDESIGN AND METHOD:We conducted a single center, two-arm, prospective, open-label, phase II study from June 2020 to December 2020 on COVID-19 patients (≥18 years), admitted at Jagjivan Ram Railway Hospital, Mumbai. The primary outcome was to evaluate the all-cause mortality up to 28 days in COVID-19 patients; secondary outcome was to assess the length of hospital stay (LOHS) and duration of respiratory supports, using PASS v11.0 software (19). RESULTS:Overallmortality status at 28 dayswas notsignicant(62 (31.2%)in the remdesivir group vs 65 (32.5%)in the control group), and themean LOHS was less in remdesivir arm which was statistically signicant in the female subgroup although the remdesivir group had delay in hospital admission from the onset of the symptoms and statistically higher index IL6 values. Duration of invasive mechanical ventilation showed signicant statistical difference among the study groups(4.7±1.18 daysin control vs 2.8±1.88 daysin remdesivir), and across both the genders. Hypertension and diabetesmellitusfoundtobe themost commoncomorbiditiesinCOVID-19.Nosafetyconcernswere reportedinRemdesivirgroup. CONCLUSION: Remdesivir was well tolerated without any adverse events, but did not show any signicant effect on COVID-19 survival rate, however it decreases the length of hospital stay and duration of invasive ventilator support. More studies are needed to understand the effects of Remdesivir in larger populations.

The Effectiveness and Side Effects of Remdesivir in COVID-19 Patients with Pneumonia

Background: Remdesivir is one of the antiviral agents to treat COVID-19 infection. It has an antiviral activity directly related to activation of pro-inflammatory responses, causing cytokine storm, multiorgan damage and mortality. With these potential activities, this study investigated the effectiveness and evaluated side effects of remdesivir used for COVID-19 patients with pneumonia. Methods: This cohort observational study collected data retrospectively from medical records of COVID-19 patients at Bhayangkara H.S Samsoeri Mertojoso Hospital, Surabaya. Patients who received remdesivir with loading dose (1 x 200 mg) IV had to follow maintenance dose (1 x 100 mg) IV. They were analyzed in three groups from October 2020 to February 2021. The data conveyed PCR/rapid Ag Swab, oxygen saturation, chest X-rays imaging, BUN, SCr, SGOT and SGPT.Result: A total of 60 patients were evaluated in three therapeutic groups, and the administration of remdesivir within 5-9 days was effective. Mostly, the patients (77%) had negative PCR/rapid Ag Swab; most of them (52%) had better oxygen saturation by supplementary oxygen therapy; more than a half had better chest X-rays imaging parameters (68%). Common side effects included an increase in SGOT (85.30%), SGPT (79.88%), BUN (74.23%), and serum creatinine (43.33%). Conclusion: The antiviral effect of remdesivir with loading dose (1 x 200 mg) IV needs to follow maintenance dose (1 x 100 mg) IV for 5-9 days. Hence, COVID-19 patients with pneumonia could have clinical improvement with increased level of liver and kidney function.

536. Clinical Outcomes of Hospitalized COVID-19 Patients Treated with Remdesivir-NEAT ID 909REM Study

536. Clinical Outcomes of Hospitalized COVID-19 Patients Treated with Remdesivir-NEAT ID 909REM Study

Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India.

IntroductionAs per the COVID-19 treatment guidelines of India, remdesivir and convalescent plasma therapy (CPT) are indicated in moderate and severe patients. In this study, we have evaluated the comparative safety and efficacy of remdesivir versus remdesivir CPT combination and effect of early versus late initiation of remdesivir.Materials and methodsA hospital-based observational study was conducted among hospitalized moderate and severe COVID-19 patients treated with either remdesivir and/or CPT as per national guidelines. Response to therapy was evaluated in terms of mortality, mechanical ventilation requirement, ICU requirement, and safety.Results and observationsA total of 95 moderate and severe COVID-19 patients on remdesivir (n=35) or remdesivir + CPT combination (n=60) were included. Both the remdesivir and remdesivir + CPT groups were comparable in terms of baseline characteristics, however, proportion of patients with baseline serum creatinine >1.5 was higher in the remdesivir group. No difference was seen between both the groups in terms of mortality, mechanical ventilation requirement, ICU requirement, and safety parameters in the overall moderate and severe COVID-19 populations and when each of these severity categories (moderate and severe) were analyzed separately. Early initiation (<9 days from symptom onset) of remdesivir was associated with better treatment outcome in terms of mortality and requirement of ICU. Post-therapy shortness of breath and LFTs (liver function tests) elevation was more in the late initiation of remdesivir group, which may be due to the lack of efficacy and subsequent disease progression or a direct effect of the drug. The beneficial effect of remdesivir was maintained even after adjustment for important prognostic factors and baseline imbalances (age, sex, disease severity, CPT use, and serum creatinine level).ConclusionsEarly initiation of remdesivir was associated with clinical benefit in terms of mortality and mechanical ventilation requirement. However, addition of convalescent plasma therapy as an additional therapeutic modality to remdesivir was not found to be beneficial.

Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis

Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis

Remdesivir (GS-5734) for COVID-19 Treatment: Past and Recent Updates

Background: SARS-CoV-2 is a pandemic now, and several measures have been taken by countries to prevent, control, and treat the disease. WHO has been working meticulously and has been providing up to date information and statistics on incidences and death. Several broad- -spectrum anti-viral drugs are available and have been used in the past to fight against the viral outbreak. Recently remdesivir, an experimental prodrug from Gilead Sciences, has been found to be a potential drug to be used as a therapy to treat COVID-19. Objective: Here, we have reviewed several previous findings from the literature and present an up to date information on remdesivir. Results : Remdesivir was initially invented for use against Ebola virus treatment and has proved effective against different strains of Ebola, Nipah, and other strains of coronaviruses. Clinical trials with remdesivir for COVID-19 patients have begun, and several off label use of remdesivir have been reported recently. Currently, the drug seems to have an effect against the SARS-CoV-2 virus, with side effects among a few patients. Although the results are not conclusive, they are partly promising. This review provides past and recent updates on the use of remdesivir. Conclusion: From the review, we conclude that the drug remdesivir is known to exhibit its mechanism of action by terminating the RNA synthesis, and it is a potential drug against the novel coronavirus.

PDG17 Adverse Drug Reactions Associated to Hydroxychloroquine and Remdesivir in COVID-19 Patients: Analysis of Reported ADR to the Portuguese Pharmacovigilance System

To analyse the adverse reactions that occurred with the two main drugs used in the context of the COVID-19 disease - Hydroxychloroquine (1st pandemic wave) and Remdesivir (2nd pandemic wave) - based on notifications of adverse reactions from Portugal.

Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective.

Remdesivir, a repurposed antiviral, was first accorded approval by the US Food Drug Administration (FDA) for the treatment of COVID-19 which necessitates hospitalization. However, the interim data of SOLIDARITY trial revealed no benefits with remdesivir for COVID-19 patients which led immediate debates in social media and the press about the utility of the drug. Both preclinical and clinical data demonstrated its efficacy in COVID-19. The recently concluded ACTT-1 trial showed its efficacy in reducing the duration of hospital stay which is of utmost importance for a country like India where reduction in bed occupancy can save lives of many and eases the financial burden of patient and government. Our benefit-risk analysis of ACTT-1 trial also favored the use of remdesivir over standard of care. The SOLIDARITY trial was fundamentally different from other clinical trials on remdesivir with respect to its design, adaptive nature, and selection of endpoints. Moreover, the success of antiviral therapy also depends on the timing of initiation and combination with other drugs. Hence we believe that drugs like Remdesivir are very important for countries like India where soft end points such as time to recovery and clinical improvement and early discharge become extremely significant during a pandemic.

Safety and Efficacy of Remdesivir for the Treatment of Covid-19: A Rapid Review of Available Evidence

Context: Remdesivir is an antiviral drug manufactured by Gilead Sciences, Inc., in which in-vitro studies have been shown to work in COVID-19 patients. Although it’s not approved by pharmaceutical authorities and has not passed the first and second phases of clinical trials, it is prescribed on a trial basis for patients with Covid-19. In more than 20 countries, researchers are monitoring the results of using Remdesivir in clinical settings to see if it can be prescribed for larger populations if patients respond positively. Methods: This is a rapid review of the evidence for the potential effects of Remdesivir, which intended to create a policy guide. To do so, health technology assessment studies indexed in MEDLINE and Cochrane Library databases were searched using the keywords, including drug name and disease name, on April 21, 2020. In addition, references of retrieved studies were checked to ensure throughout the capture of the literature. Studies on the safety and efficacy of Remdesivir in Covid-19 patients, both in Persian or English, were included. To identify ongoing clinical trials in Iran and some countries, clinical trial registration systems were also searched. Results: In total 90 titles were identified, which after removing duplicates and applying inclusion criteria, 32 were included, all of which were published in 2020. 25 of them were review studies, mostly on treating Covid-19 disease, and some of them were dedicated to the effects of Remdesivir in treating the disease. However, no systematic review was found. Of the remaining studies, three were finished clinical trials, two of which evaluated the safety and efficacy of Remdesivir on mild, moderate, and severe Covid-19 compared to a placebo, and the third study compared Remdesivir with routine treatment. A cohort study on the efficacy of Remdesivir in compassionate use was also found. Also, two case reports of patients receiving Remdesivir and a letter-to- editor describing Remdesivir as an appropriate treatment for Covid-19 were identified. Moreover, registered clinical trials with different designs intended to investigate the safety and efficacy of Remdesivir in treating Covid-19 were extracted from clinical trial registration systems (Table 3). In total 15 protocols were found, which 13 were in primary stages. The other two were in phase three of clinical trials and aimed to investigate the effect of Remdesivir in treating patients with severe, moderate, or mild Covid-19. In the clinical trial registration system, it is mentioned that the first study is stopped prematurely due to the lack of a sufficient number of patients, and the second study is also suspended. Conclusions: Evidence on the safety and efficacy of Remdesivir in treating Covid-19 are very limited to make a decision. However, if registered trials are completed, enough evidence would be available to decide whether to accept or reject the Remdesivir. Since the effectiveness of Remdesivir is not clear yet, its prescription for Covid-19 patients has so far been limited to clinical trials, compassionate use, or emergency use.